NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Novartis
Novartis
ViroMissile, Inc.
Eisai Inc.
Daiichi Sankyo
SystImmune Inc.
SAPU NANO (US) LLC
Fusion Pharmaceuticals Inc.
Alpha Fusion Inc.
Boehringer Ingelheim
ITM Solucin GmbH
AccSalus Biosciences, Inc.
AbbVie
Chongqing Precision Biotech Co., Ltd
Novelty Nobility, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Amgen
RayzeBio, Inc.
JS InnoPharm, LLC
Bayer
Nuvation Bio Inc.
Orano Med LLC
Legend Biotech USA Inc
Harbour BioMed (Guangzhou) Co. Ltd.
Hansoh BioMedical R&D Company
AffyImmune Therapeutics, Inc.
Hoffmann-La Roche
Sichuan Huiyang Life Science and Technology Corporation
Radionetics Oncology
Virogin Biotech Ltd.
Bayer
Corcept Therapeutics
Boston Pharmaceuticals
Bayer
Bayer
Bayer
Provectus Pharmaceuticals
Xencor, Inc.
Provectus Pharmaceuticals
Bayer
Xencor, Inc.
Infinity Pharmaceuticals, Inc.
Bayer
Bayer
Bayer
Bayer
Novartis
Fore Biotherapeutics
Vanquish Oncology, Inc.
Guangdong Zhongsheng Pharmaceutical Co., Ltd.